These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 28039929

  • 21. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
    Quintero Bernabeu J, Juamperez J, Mercadal-Hally M, Larrarte King M, Gallego Melcon S, Gros Subias L, Sábado Álvarez C, Soler-Palacin P, Melendo Pérez S, Esperalba J, Navarro Jiménez A, Garrido Pontnou M, Camacho Soriano J, Hidalgo Llompart E, Bilbao Aguirre I, Charco Torra R.
    Pediatr Transplant; 2022 Sep; 26(6):e14292. PubMed ID: 35466492
    [Abstract] [Full Text] [Related]

  • 22. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 23. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
    San-Juan R, Comoli P, Caillard S, Moulin B, Hirsch HH, Meylan P, ESCMID Study Group of Infection in Compromised Hosts.
    Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
    [Abstract] [Full Text] [Related]

  • 24. Epstein-Barr viral load monitoring for diagnosing post-transplant lymphoproliferative disorder in pediatric liver transplant recipients.
    Seo E, Kim J, Oh SH, Kim KM, Kim DY, Lee J.
    Pediatr Transplant; 2020 Jun; 24(4):e13666. PubMed ID: 32067332
    [Abstract] [Full Text] [Related]

  • 25. Epstein-Barr virus DNAemia in Iranian liver transplant recipients and assessment of its variation in posttransplant lymphproliferative disorder patients by quantitative polymerase chain reaction assay.
    Jamalidoust M, Geramizadeh B, Pouladfar G, Namayandeh M, Asaie S, Aliabadi N, Nikeghbalian S, Ziyaeyan M.
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():306-11. PubMed ID: 25894179
    [Abstract] [Full Text] [Related]

  • 26. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
    Doesch AO, Konstandin M, Celik S, Kristen A, Frankenstein L, Sack FU, Schnabel P, Schnitzler P, Katus HA, Dengler TJ.
    Transpl Int; 2008 Oct; 21(10):963-71. PubMed ID: 18564989
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Circulating EBV-DNA in the monitoring of EBV infection in pediatric liver transplant recipients.
    Spada M, Guizzetti M, Petz W, Colledan M, Segalin A, Lucianetti A, Bertani A, Peloni G, Sonzogni A, Alberti D, Riva S, Melzi M, Gridelli B.
    Transplant Proc; 2001 Oct; 33(1-2):1835-7. PubMed ID: 11267534
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
    Zangwill SD, Hsu DT, Kichuk MR, Garvin JH, Stolar CJ, Haddad J, Stylianos S, Michler RE, Chadburn A, Knowles DM, Addonizio LJ.
    J Heart Lung Transplant; 1998 Dec; 17(12):1161-6. PubMed ID: 9883755
    [Abstract] [Full Text] [Related]

  • 31. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
    Kim BK, Kang HJ, Hong KT, An HY, Choi JY, Lee JS, Park SS, Shin HY.
    Transpl Infect Dis; 2019 Dec; 21(6):e13182. PubMed ID: 31556214
    [Abstract] [Full Text] [Related]

  • 32. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.
    Choquet S, Varnous S, Deback C, Golmard JL, Leblond V.
    Am J Transplant; 2014 Apr; 14(4):857-66. PubMed ID: 24666832
    [Abstract] [Full Text] [Related]

  • 33. Comparison of serum and whole blood levels of cytomegalovirus and Epstein-Barr virus DNA.
    Kullberg-Lindh C, Olofsson S, Brune M, Lindh M.
    Transpl Infect Dis; 2008 Oct; 10(5):308-15. PubMed ID: 18466193
    [Abstract] [Full Text] [Related]

  • 34. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [Abstract] [Full Text] [Related]

  • 35. Surveillance of Epstein-Barr virus loads in adult liver transplantation: associations with age, sex, posttransplant times, and transplant indications.
    Schaffer K, Hassan J, Staines A, Coughlan S, Holder P, Tuite G, McCormick AP, Traynor O, Hall WW, Connell J.
    Liver Transpl; 2011 Dec; 17(12):1420-6. PubMed ID: 21837744
    [Abstract] [Full Text] [Related]

  • 36. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
    Ruf S, Behnke-Hall K, Gruhn B, Bauer J, Horn M, Beck J, Reiter A, Wagner HJ.
    J Clin Virol; 2012 Mar; 53(3):186-94. PubMed ID: 22182950
    [Abstract] [Full Text] [Related]

  • 37. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients.
    Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Barshes NR, Scott JD, Bristow LJ, O'Mahony CA, Goss JA.
    Am J Transplant; 2005 Sep; 5(9):2222-8. PubMed ID: 16095501
    [Abstract] [Full Text] [Related]

  • 38. Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study.
    Höcker B, Fickenscher H, Delecluse HJ, Böhm S, Küsters U, Schnitzler P, Pohl M, John U, Kemper MJ, Fehrenbach H, Wigger M, Holder M, Schröder M, Billing H, Fichtner A, Feneberg R, Sander A, Köpf-Shakib S, Süsal C, Tönshoff B.
    Clin Infect Dis; 2013 Jan; 56(1):84-92. PubMed ID: 23042966
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
    San-Juan R, Manuel O, Hirsch HH, Fernández-Ruiz M, López-Medrano F, Comoli P, Caillard S, Grossi P, Aguado JM, ESGICH PTLD Survey Study Group,, European Study Group of Infections in Compromised Hosts (ESGICH) from the European Society of Microbiology and Infectious Diseases (ESCMID).
    Clin Microbiol Infect; 2015 Jun; 21(6):604.e1-9. PubMed ID: 25686696
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.